



Invitation 8th Michael J. Marberger (MJM) Annual Meeting

Frontiers in Urology

Friday, 16th December 2022, 1.00 pm
Van Swieten Saal, Medical University of Vienna
Van-Swieten-Gasse 1a, 1090 Vienna

www.meduniwien.ac.at/frontiers

DEPARTMENT OF UROLOGY

 MEDICAL UNIVERSITY OF VIENNA  Vienna Healthcare Group
University Hospital Vienna

Please send your registration to mjm@meduniwien.ac.at



Van Swieten Saal, Medical University of Vienna
Van-Swieten-Gasse 1a
1090 Vienna

Contact

Department of Urology
MedUni Vienna/University Hospital Vienna
Währinger Guertel 18-20, 1090 Vienna, Austria

Phone: +43 (0)1 40400-26150
Fax: +43 (0)1 40400-23320
E-Mail: shahrokh.shariat@meduniwien.ac.at
www.meduniwien.ac.at/urology

In cooperation with
COMPREHENSIVE CANCER CENTER VIENNA



Please be aware that photographs and/or video footage will be taken at the event. These may be used for the purpose of documenting or reporting the event and published in print and online media, on various social media platforms and on MedUni Vienna's website.

Coverfoto: Elnur/Shutterstock.com

Bronze Partner



Copper Partner



In alphabetic order

Platinum Partner



Gold Partner



Silver Partner



In alphabetic order

The 8th Michael J. Marberger Annual Meeting is a hybrid, intensive, interactive, half-day educational program that brings together renowned international experts to discuss Frontiers in Urology.

The meeting will focus on key clinical topics in the management of urologic diseases including prostate, bladder and kidney cancers.

On 16th December, state-of-the-art lectures will provide clinicians and scientists with an update of the breakthroughs of 2022 to maintain their high level of care and further optimize their outcomes.

Target Audience

This educational activity is directed toward urologists and other health care providers involved in the treatment and management of patients with urologic maladies.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

- Describe the newest methods for diagnosis and information that can provide the rationale for clinical decision-making.
- Summarize recommendations that shape current strategies to care for patients.
- Develop multidisciplinary strategies to optimize outcomes for patients.
- Assess recent practice-changing clinical trial findings concerning novel tools, compounds or strategies.
- Apply emerging clinical concepts to support the management in consideration of evolving treatment paradigms in the field.

See more at:
www.meduniwien.ac.at/frontiers

Program

1.00 – 1.05 pm

Opening

Shahrokh F. Shariat, Medical University of Vienna/
University Hospital Vienna, Austria

1.05 – 2.45 pm

Session 1: General urology

Testosterone Replacement Therapy in Prostate Cancer patients, friend or foe

Bertrand Tombal, Université Catholique de Louvain (UCL), Brussels, Belgium

Minimal invasive stone management in 2022: What are the new game changers forcing the present frontiers?

Kemal Sarica, Biruni University, Istanbul, Türkiye

Updates on diagnosis and management of post prostatectomy incontinence

Sakineh Hajebrahimi, Tabriz University of Medical Sciences, Tabriz, Iran

The urologist vs the medical oncologist, who should manage advanced urologic cancers?

Brian Keith McNeil, The University Hospital of Brooklyn (UHB), New York City, USA

Thulium-Faserlaser (TFL) for stones. From bench to bedside

Dimitry Enikeev, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

2.45– 3.05 pm

Break

3.05 – 4.45 pm

Session 2: Uro-oncology

Which is the most promising approach in BCG unresponsive NMIBC?

Marek Babjuk, Charles University, Hospital Motol, Prague, Czech Republic

Minimally invasive vs. open radical nephro-ureterectomy

Paolo Gontero, Università degli Studi di Torino, Italy

Fluorescence-guided laparoscopic partial adrenalectomy

Altuğ Tuncel, Ankara City Hospital, Ankara, Türkiye

Personalized therapy of advanced urothelial carcinoma: reality or fiction?

Maria De Santis, Charité - Universitätsmedizin Berlin, Germany

Lessons learned from recent trials in kidney cancer

Manuela Schmidinger, Medical University of Vienna/
University Hospital Vienna, Austria

4.45 –5.05 pm

Coffee break

5.05 – 6.10 pm

Session 3: Prostate cancer

Prediction of therapy response in mCRPC

Péter Nyirády, Semmelweis University Urology Clinic, Budapest, Hungary

Focal Therapy for Prostate cancer: What is Old is New Again

Ganesh S. Palapattu, Michigan Medicine, University of Michigan, USA

Michael J. Marberger lecture

“What is the future of Academic Urology?”

Bertrand Tombal, Université Catholique de Louvain (UCL), Brussels, Belgium

Wrap Up

Shahrokh F. Shariat, Medical University of Vienna/
University Hospital Vienna, Austria



This event will be approved by the Austrian Medical Chamber with DFP.